more lipid drugs get indications based on HARD clinical outcomes

December 2013

You'll start to see more lipid drugs get indications based on HARD clinical outcomes...such as reducing MI or stroke risk.

Drugs are often approved just due to their ability to improve SURROGATE endpoints...lipids, blood pressure, glucose, etc.

For example, the omega-3 fatty acid, Vascepa (icosapent ethyl) is currently approved JUST to lower triglycerides ≥ 500 mg/dL...NOT to lower the risk of CV events or pancreatitis.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Opioids BIG changes with hydrocodone (Vicodin, etc)
Obesity & Weight Loss More obese patients will get bariatric surgery and need help with their meds afterward
Vaccines proper administration of vaccines
Med Adherence more reasons to improve med adherence
Acute Pain more focus on the management of ACUTE low back pain to counter the increasing use of opioids, benzodiazepines, and imaging
Pneumonia more emphasis on prevention and treatment of community-acquired pneumonia
Antidepressants two new antidepressants, Brintellix (brin-TEL-ix, vortioxetine) and Fetzima (fet-ZEE-muh, levomilnacipran)
Antipsychotics More payers are trying to rein in the use of antipsychotics in patients WITHOUT psychotic disorders
HIV & AIDS New simplified guidelines for HIV prophylaxis after a needlestick
Oral Health Patients are asking for help choosing tooth whiteners
Substance Use Disorder "Molly," the party drug
Dyslipidemia more lipid drugs get indications based on HARD clinical outcomes

more lipid drugs get indications based on HARD clinical outcomes

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents